Literature DB >> 31440911

Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).

Megan C Herink1, Yan F Zhuo2, Craig D Williams2, Thomas G DeLoughery3.   

Abstract

Compared with warfarin, the direct-acting oral anticoagulants (DOAC) have fewer pharmacokinetic drug interactions. However, significant drug interactions do exist with documented changes in DOAC concentrations, which can exceed 100%. Unlike warfarin, DOACs have no validated surrogate test to monitor the intensity of anticoagulation. However, several analyses of major outcomes trials with DOACs have demonstrated that serum concentrations do affect both the thrombotic benefits and the hemorrhagic risks of these agents. This paper reviews the known significant pharmacokinetic interactions with DOACs and includes considerations for their use in the presence of interacting medications.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31440911     DOI： 10.1007/s40265-019-01183-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  55 in total

1.  Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Authors:  Lori A Gordon; Parag Kumar; Kristina M Brooks; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jomy M George; Jay Lozier; Scott R Penzak; Colleen Hadigan
Journal:  Circulation       Date:  2016-12-06       Impact factor: 29.690

2.  Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mueck; Michael Zuehlsdorf
Journal:  Br J Clin Pharmacol       Date:  2006-11-13       Impact factor: 4.335

3.  In vivo modulation of CYP enzymes by quinidine and rifampin.

Authors:  R A Branch; A Adedoyin; R F Frye; J W Wilson; M Romkes
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

4.  Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Kathrin Reseski; Thomas Körnicke; Willy Roth
Journal:  Am J Cardiovasc Drugs       Date:  2009       Impact factor: 3.571

5.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; David A Morrow; Sabina A Murphy; Julia F Kuder; Naveen Deenadayalu; Petr Jarolim; Joshua Betcher; Minggao Shi; Karen Brown; Indravadan Patel; Michele Mercuri; Elliott M Antman
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

6.  Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.

Authors:  Blisse Vakkalagadda; Charles Frost; Wonkyung Byon; Rebecca A Boyd; Jessie Wang; Donglu Zhang; Zhigang Yu; Clapton Dias; Andrew Shenker; Frank LaCreta
Journal:  Am J Cardiovasc Drugs       Date:  2016-04       Impact factor: 3.571

7.  Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.

Authors:  Barbara S Wiggins; Amanda Northup; Dominic Johnson; Jeffrey Senfield
Journal:  Pharmacotherapy       Date:  2016-02-05       Impact factor: 4.705

8.  Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.

Authors:  Poe-Hirr Hsyu; Daniela Soriano Pignataro; Kyle Matschke
Journal:  Eur J Clin Pharmacol       Date:  2016-10-07       Impact factor: 2.953

9.  Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.

Authors:  Afraa Zrieki; Robert Farinotti; Marion Buyse
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.580

10.  An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.

Authors:  Kenneth T Moore; Seema Vaidyanathan; Jaya Natarajan; Jay Ariyawansa; Lloyd Haskell; Kenneth C Turner
Journal:  J Clin Pharmacol       Date:  2014-07-03       Impact factor: 3.126
View more
  7 in total

1.  Should we monitor the direct oral anticoagulants?

Authors:  Robert Diep; David Garcia
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

2.  Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.

Authors:  Rushikesh Potdar; Benjamin A Gartrell; Robert Given; Lawrence Karsh; Jeffrey Frankel; Karen Nenno; Kris O'MalleyLeFebvre; Amitabha Bhaumik; Sharon McCarthy; Tracy McGowan; Christopher Pieczonka
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

3.  Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity.

Authors:  Timolaos Rizos; Andreas D Meid; Andrea Huppertz; Chris Dumschat; Jan Purrucker; Kathrin I Foerster; Jürgen Burhenne; David Czock; Ekkehart Jenetzky; Peter A Ringleb; Walter E Haefeli
Journal:  J Stroke       Date:  2022-01-31       Impact factor: 6.967

Review 4.  Recent advances in the management of transient ischemic attacks.

Authors:  Jorge Ortiz-Garcia; Camilo R Gomez; Michael J Schneck; José Biller
Journal:  Fac Rev       Date:  2022-07-22

Review 5.  Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.

Authors:  Robert Benamouzig; Maxime Guenoun; David Deutsch; Laurent Fauchier
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-18       Impact factor: 3.947

Review 6.  Drug-Drug Interactions with Direct Oral Anticoagulants.

Authors:  Kathrin I Foerster; Simon Hermann; Gerd Mikus; Walter E Haefeli
Journal:  Clin Pharmacokinet       Date:  2020-08       Impact factor: 6.447

7.  Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.

Authors:  Marta Bellesini; Matteo Bianchin; Chiara Corradi; Marco Paolo Donadini; Emanuel Raschi; Alessandro Squizzato
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.